Recent stem cell advances and Sir Philip Cohen's groundbreaking research into new drug targets showcase Scotland's life sciences innovation at BIO 2009
ATLANTA, May 18 /PRNewswire/ -- At this year's BIO International Convention, May 18-21 in Atlanta, Scotland will showcase the commercial success of its research collaborations with global pharmaceutical and biotech companies, as well as major scientific advancements in stem cells, drug discovery, translational medicine, medical technology and preclinical and clinical research.
With representation from more than 30 companies and organizations, including Scottish Enterprise, Scottish Development International and TalentScotland, the Scottish Pavilion at BIO will display exceptional collaboration among industry, academia and government in its life sciences sector. Scotland's internationally-renowned universities, rich talent base and unprecedented scientific legacy make it a natural home to one of the largest and fastest growing life science clusters in Europe, with more than 620 life science organizations and over 31,000 employees.
At this year's conference, Scotland will present a panel on 'The Ubiquitin Story,' a look at an exciting new research area in which Scotland has invested heavily through the $15 million Scottish Institute for Cell Signaling (SCILLS) and the $14 million ITI Life Sciences Ubiquitin Proteasome System (UPS) drug discovery program. Participating in the panel session will be
"In these challenging times, Scotland's world-class talent, high-tech infrastructure and commitment to cross-sector collaboration provide a rich and innovative environment for life science investors," said Rhona Allison, Senior Director Life Sciences, Scottish Enterprise. "Major capital investments such as the new Edinburgh BioQuarter and the Scottish Centre for Regenerative Medicine -- led by Sir Ian Wilmut -- are only a few examples of how Scotland is helping companies quickly and effectively bring novel technologies and products to market."
Earlier this year, Scottish companies and organizations achieved stem cell breakthroughs in synthetic blood and embryonic and iPS (Induced pluripotent stem cells) technology and began stem cell clinical trials for corneal blindness and stroke, further reinforcing Scotland's world-leading position in the use of stem cell-based therapies. At BIO, government-sponsored innovation fund ITI Life Sciences and stem cell company Cellartis AB will offer insights into the company's new license to produce large volumes of high-quality, ethically-derived human embryonic stem cell lines (hES) and expand Scottish operations. NovaBiotics, one of Scotland's leading biotech companies focused on the design and development of antifungal and antibacterial therapeutics, will also be on hand to discuss the development of its lead product Novexatin(TM), a novel treatment for fungal nail infection.
Scottish Organizations at BIO Accuro Biologics Aquapharm Biodiscovery Ltd AvantiCell Science Ltd BioFilm Limited BioOutsource Biotech Innovation and Future Health Limited Cellartis AB ClinTec International Ltd CXR Biosciences Ltd Devro Medical Limited Environmental Hygiene Products Ltd Equatec Fulcrum Pharma PLC GlycoMar Limited ICON ITI Life Sciences Lamellar Biomedical Ltd Marks & Clarks LLP Murgitroyd & Company Nexxus NovaBiotics Ltd PsyRING Scottish Biomedical Scottish Development International Scottish Enterprise Scottish Stem Cell Network TalentScotland Tissue Solutions Ltd University of Dundee - MRC Protein Phosphorylation Unit University of Dundee - Research and Innovation Service University of Edinburgh - College for Medicine and Veterinary Medicine University of Edinburgh - MRC Centre for Regenerative Medicine University of Glasgow - Research and Enterprise
For further information or interviews with representatives from Scottish Development International, Scottish Enterprise, or Scottish companies attending the show, please contact Emily Hyman at 617-520-7094 or email@example.com.
|SOURCE Scottish Enterprise|
Copyright©2009 PR Newswire.
All rights reserved